Proliferative capacity of HIV-1–specific CD8 T cells in the discovery and validation cohorts
| Paired comparison . | Discovery cohort . | Validation cohort . | ||||
|---|---|---|---|---|---|---|
| Data points* . | % CFSElow CTLs, mean (SEM) . | P . | Data points* . | % CFSElow CTLs, mean (SEM) . | P . | |
| HC | 358 | 2.85 (0.37) | 149 | 1.97 (0.3) | ||
| versus | .002 | .007 | ||||
| ARTC | 273 | 0.91 (0.42) | 74 | 0.35 (0.41) | ||
| HC | 358 | 2.85 (0.42) | 149 | 1.97 (0.32) | ||
| versus | .005 | .04 | ||||
| CP | 155 | 0.74 (0.57) | 35 | 0.32 (0.64) | ||
| ARTC | 273 | 0.91 (0.18) | 74 | 0.33 (0.18) | ||
| versus | .57 | .94 | ||||
| CP | 155 | 0.75 (0.22) | 35 | 0.31 (0.25) | ||
| Paired comparison . | Discovery cohort . | Validation cohort . | ||||
|---|---|---|---|---|---|---|
| Data points* . | % CFSElow CTLs, mean (SEM) . | P . | Data points* . | % CFSElow CTLs, mean (SEM) . | P . | |
| HC | 358 | 2.85 (0.37) | 149 | 1.97 (0.3) | ||
| versus | .002 | .007 | ||||
| ARTC | 273 | 0.91 (0.42) | 74 | 0.35 (0.41) | ||
| HC | 358 | 2.85 (0.42) | 149 | 1.97 (0.32) | ||
| versus | .005 | .04 | ||||
| CP | 155 | 0.74 (0.57) | 35 | 0.32 (0.64) | ||
| ARTC | 273 | 0.91 (0.18) | 74 | 0.33 (0.18) | ||
| versus | .57 | .94 | ||||
| CP | 155 | 0.75 (0.22) | 35 | 0.31 (0.25) | ||
CTLs indicates cytotoxic T lymphocytes; HC, HIV-1 controllers; CP, chronic progressors; and ARTC, ART-treated subjects.
Number of individual epitopes tested in the CFSE-based proliferation assays.